nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—ABCB1—ovarian cancer	0.233	1	CbGaD
Methadone—CYP19A1—Paclitaxel—ovarian cancer	0.0853	0.163	CbGbCtD
Methadone—CYP3A7—Paclitaxel—ovarian cancer	0.0369	0.0707	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0369	0.0707	CbGbCtD
Methadone—ABCB1—Topotecan—ovarian cancer	0.0364	0.0697	CbGbCtD
Methadone—CYP3A5—Paclitaxel—ovarian cancer	0.0277	0.053	CbGbCtD
Methadone—CYP3A7—Docetaxel—ovarian cancer	0.0267	0.0511	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0267	0.0511	CbGbCtD
Methadone—CYP2C8—Paclitaxel—ovarian cancer	0.0266	0.051	CbGbCtD
Methadone—ABCB1—Vinorelbine—ovarian cancer	0.0257	0.0491	CbGbCtD
Methadone—CYP2D6—Vinorelbine—ovarian cancer	0.0242	0.0463	CbGbCtD
Methadone—CYP19A1—follicular fluid—ovarian cancer	0.0228	0.291	CbGeAlD
Methadone—CYP3A4—Topotecan—ovarian cancer	0.0218	0.0418	CbGbCtD
Methadone—CYP3A5—Docetaxel—ovarian cancer	0.02	0.0383	CbGbCtD
Methadone—CYP2B6—Doxorubicin—ovarian cancer	0.019	0.0363	CbGbCtD
Methadone—CYP2C9—Paclitaxel—ovarian cancer	0.0186	0.0356	CbGbCtD
Methadone—ABCB1—Paclitaxel—ovarian cancer	0.018	0.0345	CbGbCtD
Methadone—CYP3A4—Vinorelbine—ovarian cancer	0.0154	0.0294	CbGbCtD
Methadone—CYP19A1—corpus luteum—ovarian cancer	0.0132	0.168	CbGeAlD
Methadone—ABCB1—Docetaxel—ovarian cancer	0.013	0.025	CbGbCtD
Methadone—CYP3A4—Paclitaxel—ovarian cancer	0.0108	0.0207	CbGbCtD
Methadone—CYP19A1—ovarian follicle—ovarian cancer	0.0103	0.131	CbGeAlD
Methadone—ABCB1—Doxorubicin—ovarian cancer	0.00972	0.0186	CbGbCtD
Methadone—CYP2D6—Doxorubicin—ovarian cancer	0.00916	0.0175	CbGbCtD
Methadone—CYP3A4—Docetaxel—ovarian cancer	0.00781	0.015	CbGbCtD
Methadone—CYP3A4—Doxorubicin—ovarian cancer	0.00582	0.0111	CbGbCtD
Methadone—CYP2C18—uterine cervix—ovarian cancer	0.00217	0.0277	CbGeAlD
Methadone—CHRNA10—vagina—ovarian cancer	0.00214	0.0273	CbGeAlD
Methadone—CHRNA10—testis—ovarian cancer	0.00191	0.0244	CbGeAlD
Methadone—GRIN3A—testis—ovarian cancer	0.00169	0.0215	CbGeAlD
Methadone—CYP2C18—vagina—ovarian cancer	0.00147	0.0188	CbGeAlD
Methadone—OPRK1—female reproductive system—ovarian cancer	0.00141	0.018	CbGeAlD
Methadone—CHRNA10—lymph node—ovarian cancer	0.00138	0.0177	CbGeAlD
Methadone—CYP19A1—endometrium—ovarian cancer	0.00102	0.013	CbGeAlD
Methadone—CYP19A1—gonad—ovarian cancer	0.000945	0.012	CbGeAlD
Methadone—CYP19A1—uterus—ovarian cancer	0.000939	0.012	CbGeAlD
Methadone—CYP19A1—female reproductive system—ovarian cancer	0.000844	0.0108	CbGeAlD
Methadone—OPRM1—testis—ovarian cancer	0.000811	0.0103	CbGeAlD
Methadone—CYP19A1—female gonad—ovarian cancer	0.000768	0.00979	CbGeAlD
Methadone—CYP2C8—endometrium—ovarian cancer	0.00073	0.0093	CbGeAlD
Methadone—CYP3A5—uterine cervix—ovarian cancer	0.000728	0.00928	CbGeAlD
Methadone—CYP19A1—testis—ovarian cancer	0.000681	0.00868	CbGeAlD
Methadone—CYP2C19—vagina—ovarian cancer	0.000626	0.00798	CbGeAlD
Methadone—CYP2B6—gonad—ovarian cancer	0.000607	0.00774	CbGeAlD
Methadone—CYP2C8—female reproductive system—ovarian cancer	0.000604	0.0077	CbGeAlD
Methadone—CYP2C8—vagina—ovarian cancer	0.000547	0.00697	CbGeAlD
Methadone—CYP2B6—female reproductive system—ovarian cancer	0.000542	0.00691	CbGeAlD
Methadone—CYP2C9—female reproductive system—ovarian cancer	0.000537	0.00684	CbGeAlD
Methadone—ABCB1—myometrium—ovarian cancer	0.000497	0.00634	CbGeAlD
Methadone—CYP3A5—female gonad—ovarian cancer	0.000496	0.00633	CbGeAlD
Methadone—CYP19A1—lymph node—ovarian cancer	0.000494	0.00629	CbGeAlD
Methadone—CYP3A5—vagina—ovarian cancer	0.000493	0.00629	CbGeAlD
Methadone—CYP2B6—vagina—ovarian cancer	0.00049	0.00625	CbGeAlD
Methadone—CYP2C8—testis—ovarian cancer	0.000488	0.00622	CbGeAlD
Methadone—ABCB1—embryo—ovarian cancer	0.000478	0.00609	CbGeAlD
Methadone—CYP2B6—testis—ovarian cancer	0.000437	0.00558	CbGeAlD
Methadone—CYP3A4—female reproductive system—ovarian cancer	0.000409	0.00522	CbGeAlD
Methadone—CYP2D6—female reproductive system—ovarian cancer	0.000403	0.00514	CbGeAlD
Methadone—ABCB1—epithelium—ovarian cancer	0.00039	0.00497	CbGeAlD
Methadone—ABCB1—uterine cervix—ovarian cancer	0.000387	0.00493	CbGeAlD
Methadone—Decreased appetite—Melphalan—ovarian cancer	0.000379	0.00272	CcSEcCtD
Methadone—Dermatitis contact—Doxorubicin—ovarian cancer	0.000375	0.00269	CcSEcCtD
Methadone—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000373	0.00267	CcSEcCtD
Methadone—Pain—Melphalan—ovarian cancer	0.000373	0.00267	CcSEcCtD
Methadone—Tachycardia—Vinorelbine—ovarian cancer	0.000372	0.00267	CcSEcCtD
Methadone—ABCB1—decidua—ovarian cancer	0.000368	0.0047	CbGeAlD
Methadone—Hypersensitivity—Chlorambucil—ovarian cancer	0.000368	0.00264	CcSEcCtD
Methadone—Bradycardia—Paclitaxel—ovarian cancer	0.000367	0.00263	CcSEcCtD
Methadone—Feeling abnormal—Topotecan—ovarian cancer	0.000367	0.00263	CcSEcCtD
Methadone—CYP2D6—female gonad—ovarian cancer	0.000367	0.00467	CbGeAlD
Methadone—Pulmonary oedema—Epirubicin—ovarian cancer	0.000365	0.00262	CcSEcCtD
Methadone—Gastrointestinal pain—Topotecan—ovarian cancer	0.000364	0.00261	CcSEcCtD
Methadone—Anorexia—Vinorelbine—ovarian cancer	0.000363	0.0026	CcSEcCtD
Methadone—Asthenia—Chlorambucil—ovarian cancer	0.000359	0.00257	CcSEcCtD
Methadone—Hypotension—Vinorelbine—ovarian cancer	0.000356	0.00255	CcSEcCtD
Methadone—Pruritus—Chlorambucil—ovarian cancer	0.000354	0.00254	CcSEcCtD
Methadone—Urticaria—Topotecan—ovarian cancer	0.000354	0.00254	CcSEcCtD
Methadone—Abdominal pain—Topotecan—ovarian cancer	0.000352	0.00252	CcSEcCtD
Methadone—Body temperature increased—Topotecan—ovarian cancer	0.000352	0.00252	CcSEcCtD
Methadone—ABCB1—endometrium—ovarian cancer	0.00035	0.00446	CbGeAlD
Methadone—Weight increased—Docetaxel—ovarian cancer	0.000347	0.00249	CcSEcCtD
Methadone—Visual impairment—Paclitaxel—ovarian cancer	0.000347	0.00249	CcSEcCtD
Methadone—Urticaria—Melphalan—ovarian cancer	0.000346	0.00248	CcSEcCtD
Methadone—Phlebitis—Epirubicin—ovarian cancer	0.000346	0.00248	CcSEcCtD
Methadone—Weight decreased—Docetaxel—ovarian cancer	0.000345	0.00248	CcSEcCtD
Methadone—Diarrhoea—Chlorambucil—ovarian cancer	0.000342	0.00245	CcSEcCtD
Methadone—Pulmonary oedema—Doxorubicin—ovarian cancer	0.000338	0.00242	CcSEcCtD
Methadone—Flushing—Paclitaxel—ovarian cancer	0.000335	0.0024	CcSEcCtD
Methadone—Decreased appetite—Vinorelbine—ovarian cancer	0.000331	0.00237	CcSEcCtD
Methadone—Hypersensitivity—Topotecan—ovarian cancer	0.000328	0.00235	CcSEcCtD
Methadone—Constipation—Vinorelbine—ovarian cancer	0.000326	0.00234	CcSEcCtD
Methadone—Pain—Vinorelbine—ovarian cancer	0.000326	0.00234	CcSEcCtD
Methadone—CYP2D6—testis—ovarian cancer	0.000325	0.00414	CbGeAlD
Methadone—ABCB1—gonad—ovarian cancer	0.000324	0.00414	CbGeAlD
Methadone—Chills—Paclitaxel—ovarian cancer	0.000323	0.00232	CcSEcCtD
Methadone—ABCB1—uterus—ovarian cancer	0.000322	0.00411	CbGeAlD
Methadone—Arrhythmia—Paclitaxel—ovarian cancer	0.000322	0.00231	CcSEcCtD
Methadone—Hypersensitivity—Melphalan—ovarian cancer	0.000321	0.0023	CcSEcCtD
Methadone—Phlebitis—Doxorubicin—ovarian cancer	0.00032	0.0023	CcSEcCtD
Methadone—Asthenia—Topotecan—ovarian cancer	0.000319	0.00229	CcSEcCtD
Methadone—Vomiting—Chlorambucil—ovarian cancer	0.000318	0.00228	CcSEcCtD
Methadone—Pruritus—Topotecan—ovarian cancer	0.000315	0.00226	CcSEcCtD
Methadone—Erythema—Paclitaxel—ovarian cancer	0.000314	0.00225	CcSEcCtD
Methadone—Feeling abnormal—Vinorelbine—ovarian cancer	0.000314	0.00225	CcSEcCtD
Methadone—Asthenia—Melphalan—ovarian cancer	0.000313	0.00224	CcSEcCtD
Methadone—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000311	0.00223	CcSEcCtD
Methadone—Pruritus—Melphalan—ovarian cancer	0.000308	0.00221	CcSEcCtD
Methadone—Cardiac failure—Epirubicin—ovarian cancer	0.000305	0.00219	CcSEcCtD
Methadone—Diarrhoea—Topotecan—ovarian cancer	0.000305	0.00218	CcSEcCtD
Methadone—Urticaria—Vinorelbine—ovarian cancer	0.000302	0.00217	CcSEcCtD
Methadone—Muscle spasms—Paclitaxel—ovarian cancer	0.000302	0.00216	CcSEcCtD
Methadone—Body temperature increased—Vinorelbine—ovarian cancer	0.000301	0.00216	CcSEcCtD
Methadone—Abdominal pain—Vinorelbine—ovarian cancer	0.000301	0.00216	CcSEcCtD
Methadone—Diarrhoea—Melphalan—ovarian cancer	0.000298	0.00214	CcSEcCtD
Methadone—Nausea—Chlorambucil—ovarian cancer	0.000297	0.00213	CcSEcCtD
Methadone—Visual impairment—Docetaxel—ovarian cancer	0.000294	0.00211	CcSEcCtD
Methadone—Dizziness—Topotecan—ovarian cancer	0.000294	0.00211	CcSEcCtD
Methadone—Tremor—Paclitaxel—ovarian cancer	0.000294	0.00211	CcSEcCtD
Methadone—ABCB1—female reproductive system—ovarian cancer	0.00029	0.00369	CbGeAlD
Methadone—Agitation—Paclitaxel—ovarian cancer	0.000288	0.00207	CcSEcCtD
Methadone—Flushing—Docetaxel—ovarian cancer	0.000284	0.00203	CcSEcCtD
Methadone—Cardiac arrest—Epirubicin—ovarian cancer	0.000283	0.00203	CcSEcCtD
Methadone—Vomiting—Topotecan—ovarian cancer	0.000283	0.00203	CcSEcCtD
Methadone—Cardiac failure—Doxorubicin—ovarian cancer	0.000282	0.00203	CcSEcCtD
Methadone—Vertigo—Paclitaxel—ovarian cancer	0.000282	0.00202	CcSEcCtD
Methadone—Syncope—Paclitaxel—ovarian cancer	0.000281	0.00202	CcSEcCtD
Methadone—Rash—Topotecan—ovarian cancer	0.000281	0.00201	CcSEcCtD
Methadone—Hypersensitivity—Vinorelbine—ovarian cancer	0.00028	0.00201	CcSEcCtD
Methadone—Dermatitis—Topotecan—ovarian cancer	0.00028	0.00201	CcSEcCtD
Methadone—Headache—Topotecan—ovarian cancer	0.000279	0.002	CcSEcCtD
Methadone—Palpitations—Paclitaxel—ovarian cancer	0.000277	0.00199	CcSEcCtD
Methadone—Vomiting—Melphalan—ovarian cancer	0.000277	0.00199	CcSEcCtD
Methadone—Loss of consciousness—Paclitaxel—ovarian cancer	0.000276	0.00198	CcSEcCtD
Methadone—Rash—Melphalan—ovarian cancer	0.000275	0.00197	CcSEcCtD
Methadone—Dermatitis—Melphalan—ovarian cancer	0.000275	0.00197	CcSEcCtD
Methadone—Chills—Docetaxel—ovarian cancer	0.000274	0.00197	CcSEcCtD
Methadone—ABCB1—bone marrow—ovarian cancer	0.000274	0.00349	CbGeAlD
Methadone—Asthenia—Vinorelbine—ovarian cancer	0.000273	0.00196	CcSEcCtD
Methadone—Arrhythmia—Docetaxel—ovarian cancer	0.000273	0.00196	CcSEcCtD
Methadone—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000272	0.00195	CcSEcCtD
Methadone—Convulsion—Paclitaxel—ovarian cancer	0.000272	0.00195	CcSEcCtD
Methadone—Hypokalaemia—Epirubicin—ovarian cancer	0.000271	0.00195	CcSEcCtD
Methadone—Pruritus—Vinorelbine—ovarian cancer	0.000269	0.00193	CcSEcCtD
Methadone—Nasopharyngitis—Epirubicin—ovarian cancer	0.000266	0.00191	CcSEcCtD
Methadone—Anxiety—Paclitaxel—ovarian cancer	0.000266	0.00191	CcSEcCtD
Methadone—Erythema—Docetaxel—ovarian cancer	0.000266	0.00191	CcSEcCtD
Methadone—Nausea—Topotecan—ovarian cancer	0.000264	0.0019	CcSEcCtD
Methadone—ABCB1—female gonad—ovarian cancer	0.000264	0.00336	CbGeAlD
Methadone—Cardiac arrest—Doxorubicin—ovarian cancer	0.000262	0.00188	CcSEcCtD
Methadone—ABCB1—vagina—ovarian cancer	0.000262	0.00334	CbGeAlD
Methadone—Dry mouth—Paclitaxel—ovarian cancer	0.000261	0.00187	CcSEcCtD
Methadone—Diarrhoea—Vinorelbine—ovarian cancer	0.00026	0.00187	CcSEcCtD
Methadone—Nausea—Melphalan—ovarian cancer	0.000259	0.00186	CcSEcCtD
Methadone—Confusional state—Paclitaxel—ovarian cancer	0.000258	0.00185	CcSEcCtD
Methadone—Oedema—Paclitaxel—ovarian cancer	0.000256	0.00184	CcSEcCtD
Methadone—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000256	0.00184	CcSEcCtD
Methadone—Muscle spasms—Docetaxel—ovarian cancer	0.000256	0.00183	CcSEcCtD
Methadone—Shock—Paclitaxel—ovarian cancer	0.000252	0.00181	CcSEcCtD
Methadone—Dizziness—Vinorelbine—ovarian cancer	0.000252	0.00181	CcSEcCtD
Methadone—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000252	0.00181	CcSEcCtD
Methadone—Hypokalaemia—Doxorubicin—ovarian cancer	0.000251	0.0018	CcSEcCtD
Methadone—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000251	0.0018	CcSEcCtD
Methadone—Tachycardia—Paclitaxel—ovarian cancer	0.00025	0.00179	CcSEcCtD
Methadone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000248	0.00178	CcSEcCtD
Methadone—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000246	0.00177	CcSEcCtD
Methadone—Anorexia—Paclitaxel—ovarian cancer	0.000244	0.00175	CcSEcCtD
Methadone—Vomiting—Vinorelbine—ovarian cancer	0.000242	0.00174	CcSEcCtD
Methadone—Rash—Vinorelbine—ovarian cancer	0.00024	0.00172	CcSEcCtD
Methadone—Dermatitis—Vinorelbine—ovarian cancer	0.00024	0.00172	CcSEcCtD
Methadone—Hypotension—Paclitaxel—ovarian cancer	0.000239	0.00172	CcSEcCtD
Methadone—Headache—Vinorelbine—ovarian cancer	0.000239	0.00171	CcSEcCtD
Methadone—Syncope—Docetaxel—ovarian cancer	0.000239	0.00171	CcSEcCtD
Methadone—Palpitations—Docetaxel—ovarian cancer	0.000235	0.00169	CcSEcCtD
Methadone—Weight increased—Epirubicin—ovarian cancer	0.000234	0.00168	CcSEcCtD
Methadone—ABCB1—testis—ovarian cancer	0.000234	0.00298	CbGeAlD
Methadone—Loss of consciousness—Docetaxel—ovarian cancer	0.000234	0.00168	CcSEcCtD
Methadone—Weight decreased—Epirubicin—ovarian cancer	0.000233	0.00167	CcSEcCtD
Methadone—Insomnia—Paclitaxel—ovarian cancer	0.000232	0.00166	CcSEcCtD
Methadone—Convulsion—Docetaxel—ovarian cancer	0.00023	0.00165	CcSEcCtD
Methadone—Drowsiness—Epirubicin—ovarian cancer	0.00023	0.00165	CcSEcCtD
Methadone—Somnolence—Paclitaxel—ovarian cancer	0.000228	0.00163	CcSEcCtD
Methadone—Nausea—Vinorelbine—ovarian cancer	0.000226	0.00162	CcSEcCtD
Methadone—Decreased appetite—Paclitaxel—ovarian cancer	0.000223	0.0016	CcSEcCtD
Methadone—Dry mouth—Docetaxel—ovarian cancer	0.000221	0.00159	CcSEcCtD
Methadone—Sweating—Epirubicin—ovarian cancer	0.00022	0.00158	CcSEcCtD
Methadone—Pain—Paclitaxel—ovarian cancer	0.000219	0.00157	CcSEcCtD
Methadone—Constipation—Paclitaxel—ovarian cancer	0.000219	0.00157	CcSEcCtD
Methadone—Confusional state—Docetaxel—ovarian cancer	0.000219	0.00157	CcSEcCtD
Methadone—Oedema—Docetaxel—ovarian cancer	0.000217	0.00156	CcSEcCtD
Methadone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000217	0.00156	CcSEcCtD
Methadone—Weight increased—Doxorubicin—ovarian cancer	0.000217	0.00156	CcSEcCtD
Methadone—Weight decreased—Doxorubicin—ovarian cancer	0.000216	0.00155	CcSEcCtD
Methadone—Shock—Docetaxel—ovarian cancer	0.000214	0.00153	CcSEcCtD
Methadone—Thrombocytopenia—Docetaxel—ovarian cancer	0.000213	0.00152	CcSEcCtD
Methadone—Drowsiness—Doxorubicin—ovarian cancer	0.000212	0.00152	CcSEcCtD
Methadone—Tachycardia—Docetaxel—ovarian cancer	0.000212	0.00152	CcSEcCtD
Methadone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000211	0.00151	CcSEcCtD
Methadone—Bradycardia—Epirubicin—ovarian cancer	0.00021	0.00151	CcSEcCtD
Methadone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000209	0.0015	CcSEcCtD
Methadone—Anorexia—Docetaxel—ovarian cancer	0.000207	0.00148	CcSEcCtD
Methadone—Sweating—Doxorubicin—ovarian cancer	0.000204	0.00146	CcSEcCtD
Methadone—Urticaria—Paclitaxel—ovarian cancer	0.000203	0.00146	CcSEcCtD
Methadone—Tamoxifen—CYP1B1—ovarian cancer	0.000203	0.223	CrCbGaD
Methadone—Hypotension—Docetaxel—ovarian cancer	0.000203	0.00146	CcSEcCtD
Methadone—Body temperature increased—Paclitaxel—ovarian cancer	0.000202	0.00145	CcSEcCtD
Methadone—Abdominal pain—Paclitaxel—ovarian cancer	0.000202	0.00145	CcSEcCtD
Methadone—Visual impairment—Epirubicin—ovarian cancer	0.000199	0.00142	CcSEcCtD
Methadone—Insomnia—Docetaxel—ovarian cancer	0.000196	0.00141	CcSEcCtD
Methadone—Bradycardia—Doxorubicin—ovarian cancer	0.000194	0.00139	CcSEcCtD
Methadone—Somnolence—Docetaxel—ovarian cancer	0.000193	0.00138	CcSEcCtD
Methadone—Flushing—Epirubicin—ovarian cancer	0.000191	0.00137	CcSEcCtD
Methadone—Decreased appetite—Docetaxel—ovarian cancer	0.000189	0.00135	CcSEcCtD
Methadone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000189	0.00135	CcSEcCtD
Methadone—Pain—Docetaxel—ovarian cancer	0.000186	0.00133	CcSEcCtD
Methadone—Constipation—Docetaxel—ovarian cancer	0.000186	0.00133	CcSEcCtD
Methadone—Chills—Epirubicin—ovarian cancer	0.000185	0.00133	CcSEcCtD
Methadone—Arrhythmia—Epirubicin—ovarian cancer	0.000184	0.00132	CcSEcCtD
Methadone—Visual impairment—Doxorubicin—ovarian cancer	0.000184	0.00132	CcSEcCtD
Methadone—Asthenia—Paclitaxel—ovarian cancer	0.000184	0.00132	CcSEcCtD
Methadone—Pruritus—Paclitaxel—ovarian cancer	0.000181	0.0013	CcSEcCtD
Methadone—Erythema—Epirubicin—ovarian cancer	0.000179	0.00129	CcSEcCtD
Methadone—Feeling abnormal—Docetaxel—ovarian cancer	0.000179	0.00128	CcSEcCtD
Methadone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000177	0.00127	CcSEcCtD
Methadone—Flushing—Doxorubicin—ovarian cancer	0.000177	0.00127	CcSEcCtD
Methadone—Diarrhoea—Paclitaxel—ovarian cancer	0.000175	0.00126	CcSEcCtD
Methadone—Muscle spasms—Epirubicin—ovarian cancer	0.000172	0.00124	CcSEcCtD
Methadone—Abdominal pain—Docetaxel—ovarian cancer	0.000172	0.00123	CcSEcCtD
Methadone—Body temperature increased—Docetaxel—ovarian cancer	0.000172	0.00123	CcSEcCtD
Methadone—Chills—Doxorubicin—ovarian cancer	0.000171	0.00123	CcSEcCtD
Methadone—Arrhythmia—Doxorubicin—ovarian cancer	0.00017	0.00122	CcSEcCtD
Methadone—ABCB1—lymph node—ovarian cancer	0.00017	0.00216	CbGeAlD
Methadone—Dizziness—Paclitaxel—ovarian cancer	0.000169	0.00122	CcSEcCtD
Methadone—Erythema—Doxorubicin—ovarian cancer	0.000166	0.00119	CcSEcCtD
Methadone—Agitation—Epirubicin—ovarian cancer	0.000165	0.00118	CcSEcCtD
Methadone—Vomiting—Paclitaxel—ovarian cancer	0.000163	0.00117	CcSEcCtD
Methadone—Rash—Paclitaxel—ovarian cancer	0.000161	0.00116	CcSEcCtD
Methadone—Dermatitis—Paclitaxel—ovarian cancer	0.000161	0.00116	CcSEcCtD
Methadone—Vertigo—Epirubicin—ovarian cancer	0.000161	0.00116	CcSEcCtD
Methadone—Syncope—Epirubicin—ovarian cancer	0.000161	0.00115	CcSEcCtD
Methadone—Headache—Paclitaxel—ovarian cancer	0.00016	0.00115	CcSEcCtD
Methadone—Hypersensitivity—Docetaxel—ovarian cancer	0.00016	0.00115	CcSEcCtD
Methadone—Muscle spasms—Doxorubicin—ovarian cancer	0.00016	0.00114	CcSEcCtD
Methadone—Palpitations—Epirubicin—ovarian cancer	0.000159	0.00114	CcSEcCtD
Methadone—Loss of consciousness—Epirubicin—ovarian cancer	0.000158	0.00113	CcSEcCtD
Methadone—Asthenia—Docetaxel—ovarian cancer	0.000156	0.00112	CcSEcCtD
Methadone—Convulsion—Epirubicin—ovarian cancer	0.000155	0.00112	CcSEcCtD
Methadone—Pruritus—Docetaxel—ovarian cancer	0.000154	0.0011	CcSEcCtD
Methadone—Agitation—Doxorubicin—ovarian cancer	0.000153	0.00109	CcSEcCtD
Methadone—Anxiety—Epirubicin—ovarian cancer	0.000152	0.00109	CcSEcCtD
Methadone—Nausea—Paclitaxel—ovarian cancer	0.000152	0.00109	CcSEcCtD
Methadone—Dry mouth—Epirubicin—ovarian cancer	0.000149	0.00107	CcSEcCtD
Methadone—Vertigo—Doxorubicin—ovarian cancer	0.000149	0.00107	CcSEcCtD
Methadone—Syncope—Doxorubicin—ovarian cancer	0.000149	0.00107	CcSEcCtD
Methadone—Diarrhoea—Docetaxel—ovarian cancer	0.000149	0.00107	CcSEcCtD
Methadone—Confusional state—Epirubicin—ovarian cancer	0.000148	0.00106	CcSEcCtD
Methadone—Palpitations—Doxorubicin—ovarian cancer	0.000147	0.00105	CcSEcCtD
Methadone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000146	0.00105	CcSEcCtD
Methadone—Oedema—Epirubicin—ovarian cancer	0.000146	0.00105	CcSEcCtD
Methadone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000146	0.00105	CcSEcCtD
Methadone—Shock—Epirubicin—ovarian cancer	0.000144	0.00103	CcSEcCtD
Methadone—Convulsion—Doxorubicin—ovarian cancer	0.000144	0.00103	CcSEcCtD
Methadone—Dizziness—Docetaxel—ovarian cancer	0.000144	0.00103	CcSEcCtD
Methadone—Thrombocytopenia—Epirubicin—ovarian cancer	0.000143	0.00103	CcSEcCtD
Methadone—Tachycardia—Epirubicin—ovarian cancer	0.000143	0.00103	CcSEcCtD
Methadone—Hyperhidrosis—Epirubicin—ovarian cancer	0.000142	0.00102	CcSEcCtD
Methadone—Anxiety—Doxorubicin—ovarian cancer	0.000141	0.00101	CcSEcCtD
Methadone—Anorexia—Epirubicin—ovarian cancer	0.00014	0.001	CcSEcCtD
Methadone—Dry mouth—Doxorubicin—ovarian cancer	0.000138	0.000992	CcSEcCtD
Methadone—Vomiting—Docetaxel—ovarian cancer	0.000138	0.00099	CcSEcCtD
Methadone—Tamoxifen—ESR1—ovarian cancer	0.000137	0.151	CrCbGaD
Methadone—Rash—Docetaxel—ovarian cancer	0.000137	0.000982	CcSEcCtD
Methadone—Hypotension—Epirubicin—ovarian cancer	0.000137	0.000982	CcSEcCtD
Methadone—Dermatitis—Docetaxel—ovarian cancer	0.000137	0.000981	CcSEcCtD
Methadone—Confusional state—Doxorubicin—ovarian cancer	0.000137	0.00098	CcSEcCtD
Methadone—Headache—Docetaxel—ovarian cancer	0.000136	0.000976	CcSEcCtD
Methadone—Oedema—Doxorubicin—ovarian cancer	0.000135	0.000972	CcSEcCtD
Methadone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000135	0.000972	CcSEcCtD
Methadone—Shock—Doxorubicin—ovarian cancer	0.000133	0.000956	CcSEcCtD
Methadone—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000133	0.000952	CcSEcCtD
Methadone—Insomnia—Epirubicin—ovarian cancer	0.000132	0.00095	CcSEcCtD
Methadone—Tachycardia—Doxorubicin—ovarian cancer	0.000132	0.000949	CcSEcCtD
Methadone—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000131	0.00094	CcSEcCtD
Methadone—Somnolence—Epirubicin—ovarian cancer	0.00013	0.000934	CcSEcCtD
Methadone—Anorexia—Doxorubicin—ovarian cancer	0.000129	0.000926	CcSEcCtD
Methadone—Nausea—Docetaxel—ovarian cancer	0.000129	0.000925	CcSEcCtD
Methadone—Fexofenadine—ABCB1—ovarian cancer	0.000127	0.14	CrCbGaD
Methadone—Decreased appetite—Epirubicin—ovarian cancer	0.000127	0.000913	CcSEcCtD
Methadone—Hypotension—Doxorubicin—ovarian cancer	0.000127	0.000908	CcSEcCtD
Methadone—Constipation—Epirubicin—ovarian cancer	0.000125	0.000898	CcSEcCtD
Methadone—Pain—Epirubicin—ovarian cancer	0.000125	0.000898	CcSEcCtD
Methadone—Insomnia—Doxorubicin—ovarian cancer	0.000123	0.000879	CcSEcCtD
Methadone—Feeling abnormal—Epirubicin—ovarian cancer	0.000121	0.000866	CcSEcCtD
Methadone—Somnolence—Doxorubicin—ovarian cancer	0.00012	0.000864	CcSEcCtD
Methadone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00012	0.000859	CcSEcCtD
Methadone—Decreased appetite—Doxorubicin—ovarian cancer	0.000118	0.000845	CcSEcCtD
Methadone—Urticaria—Epirubicin—ovarian cancer	0.000116	0.000834	CcSEcCtD
Methadone—Constipation—Doxorubicin—ovarian cancer	0.000116	0.000831	CcSEcCtD
Methadone—Pain—Doxorubicin—ovarian cancer	0.000116	0.000831	CcSEcCtD
Methadone—Abdominal pain—Epirubicin—ovarian cancer	0.000116	0.00083	CcSEcCtD
Methadone—Body temperature increased—Epirubicin—ovarian cancer	0.000116	0.00083	CcSEcCtD
Methadone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000112	0.000801	CcSEcCtD
Methadone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000111	0.000795	CcSEcCtD
Methadone—Hypersensitivity—Epirubicin—ovarian cancer	0.000108	0.000774	CcSEcCtD
Methadone—Urticaria—Doxorubicin—ovarian cancer	0.000108	0.000772	CcSEcCtD
Methadone—Abdominal pain—Doxorubicin—ovarian cancer	0.000107	0.000768	CcSEcCtD
Methadone—Body temperature increased—Doxorubicin—ovarian cancer	0.000107	0.000768	CcSEcCtD
Methadone—Asthenia—Epirubicin—ovarian cancer	0.000105	0.000754	CcSEcCtD
Methadone—Pruritus—Epirubicin—ovarian cancer	0.000104	0.000743	CcSEcCtD
Methadone—Diarrhoea—Epirubicin—ovarian cancer	0.0001	0.000719	CcSEcCtD
Methadone—Hypersensitivity—Doxorubicin—ovarian cancer	9.98e-05	0.000716	CcSEcCtD
Methadone—Clotrimazole—ABCB1—ovarian cancer	9.85e-05	0.108	CrCbGaD
Methadone—Asthenia—Doxorubicin—ovarian cancer	9.72e-05	0.000697	CcSEcCtD
Methadone—Dizziness—Epirubicin—ovarian cancer	9.68e-05	0.000695	CcSEcCtD
Methadone—Pruritus—Doxorubicin—ovarian cancer	9.58e-05	0.000688	CcSEcCtD
Methadone—Vomiting—Epirubicin—ovarian cancer	9.31e-05	0.000668	CcSEcCtD
Methadone—Diarrhoea—Doxorubicin—ovarian cancer	9.27e-05	0.000665	CcSEcCtD
Methadone—Rash—Epirubicin—ovarian cancer	9.23e-05	0.000662	CcSEcCtD
Methadone—Dermatitis—Epirubicin—ovarian cancer	9.22e-05	0.000662	CcSEcCtD
Methadone—Headache—Epirubicin—ovarian cancer	9.17e-05	0.000658	CcSEcCtD
Methadone—Dizziness—Doxorubicin—ovarian cancer	8.96e-05	0.000643	CcSEcCtD
Methadone—Nausea—Epirubicin—ovarian cancer	8.7e-05	0.000624	CcSEcCtD
Methadone—Vomiting—Doxorubicin—ovarian cancer	8.61e-05	0.000618	CcSEcCtD
Methadone—Rash—Doxorubicin—ovarian cancer	8.54e-05	0.000613	CcSEcCtD
Methadone—Dermatitis—Doxorubicin—ovarian cancer	8.53e-05	0.000612	CcSEcCtD
Methadone—Headache—Doxorubicin—ovarian cancer	8.49e-05	0.000609	CcSEcCtD
Methadone—Fentanyl—ABCB1—ovarian cancer	8.42e-05	0.0927	CrCbGaD
Methadone—Loperamide—ABCB1—ovarian cancer	8.11e-05	0.0893	CrCbGaD
Methadone—Nausea—Doxorubicin—ovarian cancer	8.05e-05	0.000577	CcSEcCtD
Methadone—Trimipramine—ABCB1—ovarian cancer	6.09e-05	0.067	CrCbGaD
Methadone—Promethazine—ABCB1—ovarian cancer	5.87e-05	0.0645	CrCbGaD
Methadone—Tamoxifen—ABCB1—ovarian cancer	5.82e-05	0.0641	CrCbGaD
Methadone—CYP3A7—Metabolism—CAV1—ovarian cancer	6.32e-06	0.000243	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	6.22e-06	0.000239	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.2e-06	0.000238	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.18e-06	0.000238	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CAV1—ovarian cancer	6.15e-06	0.000236	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CYP1B1—ovarian cancer	6.07e-06	0.000234	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—MAPK1—ovarian cancer	6.04e-06	0.000232	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—EGFR—ovarian cancer	6.04e-06	0.000232	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—PIK3CA—ovarian cancer	5.97e-06	0.00023	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—FASN—ovarian cancer	5.95e-06	0.000229	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ESR1—ovarian cancer	5.92e-06	0.000228	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ABCB1—ovarian cancer	5.91e-06	0.000227	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—ERBB2—ovarian cancer	5.87e-06	0.000226	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—SLC5A5—ovarian cancer	5.86e-06	0.000225	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CD—ovarian cancer	5.83e-06	0.000224	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL6ST—ovarian cancer	5.83e-06	0.000224	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CD—ovarian cancer	5.82e-06	0.000224	CbGpPWpGaD
Methadone—ABCB1—Metabolism—FASN—ovarian cancer	5.81e-06	0.000223	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—TYMS—ovarian cancer	5.8e-06	0.000223	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.79e-06	0.000223	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MTOR—ovarian cancer	5.79e-06	0.000223	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PIK3CB—ovarian cancer	5.79e-06	0.000223	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ABCB1—ovarian cancer	5.78e-06	0.000222	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—PIK3CA—ovarian cancer	5.77e-06	0.000222	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CG—ovarian cancer	5.76e-06	0.000221	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PTEN—ovarian cancer	5.74e-06	0.00022	CbGpPWpGaD
Methadone—ABCB1—Metabolism—SLC5A5—ovarian cancer	5.72e-06	0.00022	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—KRAS—ovarian cancer	5.7e-06	0.000219	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—YAP1—ovarian cancer	5.69e-06	0.000219	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—TYMS—ovarian cancer	5.67e-06	0.000218	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—SLC2A1—ovarian cancer	5.66e-06	0.000217	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.63e-06	0.000216	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—APC—ovarian cancer	5.6e-06	0.000215	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CG—ovarian cancer	5.6e-06	0.000215	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—NRAS—ovarian cancer	5.6e-06	0.000215	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL8—ovarian cancer	5.56e-06	0.000214	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.54e-06	0.000213	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—HRAS—ovarian cancer	5.53e-06	0.000212	CbGpPWpGaD
Methadone—ABCB1—Metabolism—SLC2A1—ovarian cancer	5.52e-06	0.000212	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—FASN—ovarian cancer	5.48e-06	0.00021	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CDKN1B—ovarian cancer	5.43e-06	0.000209	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—FASN—ovarian cancer	5.43e-06	0.000209	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CYP1B1—ovarian cancer	5.42e-06	0.000208	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	5.39e-06	0.000207	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—SLC5A5—ovarian cancer	5.39e-06	0.000207	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—AKT1—ovarian cancer	5.37e-06	0.000207	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—MAPK3—ovarian cancer	5.36e-06	0.000206	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.36e-06	0.000206	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—SLC5A5—ovarian cancer	5.34e-06	0.000205	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CASP3—ovarian cancer	5.33e-06	0.000205	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL2—ovarian cancer	5.32e-06	0.000204	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CYP1B1—ovarian cancer	5.29e-06	0.000203	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL6—ovarian cancer	5.29e-06	0.000203	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—PIK3CA—ovarian cancer	5.24e-06	0.000201	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—SLC2A1—ovarian cancer	5.2e-06	0.0002	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCND1—ovarian cancer	5.18e-06	0.000199	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—SLC2A1—ovarian cancer	5.16e-06	0.000198	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ERBB2—ovarian cancer	5.14e-06	0.000198	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CTNNB1—ovarian cancer	5.13e-06	0.000197	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—MAPK1—ovarian cancer	5.1e-06	0.000196	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—EGFR—ovarian cancer	5.1e-06	0.000196	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CB—ovarian cancer	5.08e-06	0.000195	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CB—ovarian cancer	5.08e-06	0.000195	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MTOR—ovarian cancer	5.08e-06	0.000195	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CD—ovarian cancer	5.06e-06	0.000195	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.05e-06	0.000194	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MMP9—ovarian cancer	5.03e-06	0.000193	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PTEN—ovarian cancer	5e-06	0.000192	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ABCB1—ovarian cancer	5e-06	0.000192	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CYP1B1—ovarian cancer	4.99e-06	0.000192	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.95e-06	0.00019	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CYP1B1—ovarian cancer	4.94e-06	0.00019	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CD—ovarian cancer	4.92e-06	0.000189	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—TYMS—ovarian cancer	4.91e-06	0.000189	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AKT1—ovarian cancer	4.88e-06	0.000188	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—ovarian cancer	4.88e-06	0.000188	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	4.88e-06	0.000187	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—HRAS—ovarian cancer	4.85e-06	0.000186	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—KRAS—ovarian cancer	4.82e-06	0.000185	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	4.81e-06	0.000185	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.79e-06	0.000184	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CDKN1B—ovarian cancer	4.76e-06	0.000183	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AKT1—ovarian cancer	4.71e-06	0.000181	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPP2R1A—ovarian cancer	4.69e-06	0.00018	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CAV1—ovarian cancer	4.68e-06	0.00018	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CASP3—ovarian cancer	4.67e-06	0.000179	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL2—ovarian cancer	4.66e-06	0.000179	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL6—ovarian cancer	4.64e-06	0.000178	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—FASN—ovarian cancer	4.64e-06	0.000178	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CAV1—ovarian cancer	4.57e-06	0.000176	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—SLC5A5—ovarian cancer	4.56e-06	0.000175	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCND1—ovarian cancer	4.55e-06	0.000175	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—VEGFA—ovarian cancer	4.52e-06	0.000174	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CTNNB1—ovarian cancer	4.5e-06	0.000173	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—STAT3—ovarian cancer	4.47e-06	0.000172	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ABCB1—ovarian cancer	4.47e-06	0.000172	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—NRAS—ovarian cancer	4.46e-06	0.000172	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—PIK3CA—ovarian cancer	4.43e-06	0.00017	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	4.42e-06	0.00017	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CB—ovarian cancer	4.41e-06	0.00017	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MMP9—ovarian cancer	4.41e-06	0.00017	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—SLC2A1—ovarian cancer	4.41e-06	0.000169	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—YAP1—ovarian cancer	4.39e-06	0.000169	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTEN—ovarian cancer	4.39e-06	0.000169	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PTEN—ovarian cancer	4.39e-06	0.000169	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—TYMS—ovarian cancer	4.39e-06	0.000169	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	4.38e-06	0.000169	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.36e-06	0.000168	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ERBB2—ovarian cancer	4.35e-06	0.000167	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.31e-06	0.000166	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CB—ovarian cancer	4.29e-06	0.000165	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MTOR—ovarian cancer	4.29e-06	0.000165	CbGpPWpGaD
Methadone—ABCB1—Metabolism—TYMS—ovarian cancer	4.28e-06	0.000165	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AKT1—ovarian cancer	4.28e-06	0.000165	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MAPK3—ovarian cancer	4.27e-06	0.000164	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CG—ovarian cancer	4.26e-06	0.000164	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CYP1B1—ovarian cancer	4.22e-06	0.000162	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CG—ovarian cancer	4.16e-06	0.00016	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MYC—ovarian cancer	4.16e-06	0.00016	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—ovarian cancer	4.12e-06	0.000158	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ABCB1—ovarian cancer	4.11e-06	0.000158	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—HRAS—ovarian cancer	4.1e-06	0.000157	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ABCB1—ovarian cancer	4.07e-06	0.000157	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MAPK1—ovarian cancer	4.07e-06	0.000156	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EGFR—ovarian cancer	4.07e-06	0.000156	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PIK3CA—ovarian cancer	4.05e-06	0.000156	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—TYMS—ovarian cancer	4.03e-06	0.000155	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CDKN1B—ovarian cancer	4.03e-06	0.000155	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—TYMS—ovarian cancer	4e-06	0.000154	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AKT1—ovarian cancer	3.98e-06	0.000153	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—VEGFA—ovarian cancer	3.96e-06	0.000152	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CAV1—ovarian cancer	3.96e-06	0.000152	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CASP3—ovarian cancer	3.95e-06	0.000152	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL2—ovarian cancer	3.94e-06	0.000151	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—STAT3—ovarian cancer	3.92e-06	0.000151	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL6—ovarian cancer	3.92e-06	0.000151	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NRAS—ovarian cancer	3.91e-06	0.00015	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—KRAS—ovarian cancer	3.84e-06	0.000148	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCND1—ovarian cancer	3.84e-06	0.000148	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTEN—ovarian cancer	3.81e-06	0.000147	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CTNNB1—ovarian cancer	3.8e-06	0.000146	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.78e-06	0.000145	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MAPK3—ovarian cancer	3.75e-06	0.000144	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	3.75e-06	0.000144	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CD—ovarian cancer	3.74e-06	0.000144	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MMP9—ovarian cancer	3.73e-06	0.000143	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.73e-06	0.000143	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PTEN—ovarian cancer	3.71e-06	0.000143	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CD—ovarian cancer	3.66e-06	0.000141	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MYC—ovarian cancer	3.65e-06	0.00014	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AKT1—ovarian cancer	3.62e-06	0.000139	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CG—ovarian cancer	3.61e-06	0.000139	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—FASN—ovarian cancer	3.58e-06	0.000138	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MAPK1—ovarian cancer	3.57e-06	0.000137	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGFR—ovarian cancer	3.57e-06	0.000137	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CAV1—ovarian cancer	3.53e-06	0.000136	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PIK3CA—ovarian cancer	3.53e-06	0.000136	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.52e-06	0.000135	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.48e-06	0.000134	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CAV1—ovarian cancer	3.45e-06	0.000133	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—TYMS—ovarian cancer	3.42e-06	0.000131	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TP53—ovarian cancer	3.41e-06	0.000131	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.4e-06	0.000131	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.38e-06	0.00013	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—KRAS—ovarian cancer	3.37e-06	0.000129	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—VEGFA—ovarian cancer	3.35e-06	0.000129	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—STAT3—ovarian cancer	3.32e-06	0.000127	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NRAS—ovarian cancer	3.31e-06	0.000127	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—AKT1—ovarian cancer	3.31e-06	0.000127	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—HRAS—ovarian cancer	3.27e-06	0.000126	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CB—ovarian cancer	3.26e-06	0.000125	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.26e-06	0.000125	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CAV1—ovarian cancer	3.25e-06	0.000125	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CAV1—ovarian cancer	3.22e-06	0.000124	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CG—ovarian cancer	3.22e-06	0.000124	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CB—ovarian cancer	3.19e-06	0.000123	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CD—ovarian cancer	3.17e-06	0.000122	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MAPK3—ovarian cancer	3.17e-06	0.000122	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CG—ovarian cancer	3.14e-06	0.000121	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL6—ovarian cancer	3.13e-06	0.00012	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CA—ovarian cancer	3.1e-06	0.000119	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CA—ovarian cancer	3.09e-06	0.000119	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MYC—ovarian cancer	3.08e-06	0.000118	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.08e-06	0.000118	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MAPK1—ovarian cancer	3.01e-06	0.000116	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGFR—ovarian cancer	3.01e-06	0.000116	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TP53—ovarian cancer	2.99e-06	0.000115	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.96e-06	0.000114	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.93e-06	0.000113	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.89e-06	0.000111	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AKT1—ovarian cancer	2.88e-06	0.000111	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—HRAS—ovarian cancer	2.86e-06	0.00011	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KRAS—ovarian cancer	2.85e-06	0.000109	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.83e-06	0.000109	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTEN—ovarian cancer	2.82e-06	0.000108	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CB—ovarian cancer	2.76e-06	0.000106	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.76e-06	0.000106	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTEN—ovarian cancer	2.76e-06	0.000106	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CAV1—ovarian cancer	2.75e-06	0.000106	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL6—ovarian cancer	2.74e-06	0.000105	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.69e-06	0.000103	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.69e-06	0.000103	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—TYMS—ovarian cancer	2.64e-06	0.000101	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.63e-06	0.000101	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CA—ovarian cancer	2.62e-06	0.000101	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.6e-06	0.0001	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.58e-06	9.92e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—AKT1—ovarian cancer	2.53e-06	9.73e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TP53—ovarian cancer	2.53e-06	9.73e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AKT1—ovarian cancer	2.53e-06	9.72e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.51e-06	9.64e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CB—ovarian cancer	2.47e-06	9.48e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—HRAS—ovarian cancer	2.42e-06	9.3e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.41e-06	9.25e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTEN—ovarian cancer	2.39e-06	9.18e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL6—ovarian cancer	2.32e-06	8.9e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.27e-06	8.72e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.25e-06	8.64e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.2e-06	8.47e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—AKT1—ovarian cancer	2.2e-06	8.45e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AKT1—ovarian cancer	2.14e-06	8.21e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTEN—ovarian cancer	2.13e-06	8.19e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CAV1—ovarian cancer	2.12e-06	8.17e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTEN—ovarian cancer	2.08e-06	8e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CA—ovarian cancer	1.99e-06	7.65e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTEN—ovarian cancer	1.96e-06	7.53e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.94e-06	7.48e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTEN—ovarian cancer	1.94e-06	7.47e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.94e-06	7.44e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.92e-06	7.39e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.7e-06	6.54e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.68e-06	6.47e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTEN—ovarian cancer	1.66e-06	6.38e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AKT1—ovarian cancer	1.63e-06	6.25e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AKT1—ovarian cancer	1.59e-06	6.11e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.5e-06	5.78e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.48e-06	5.7e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.47e-06	5.64e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.38e-06	5.32e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AKT1—ovarian cancer	1.38e-06	5.29e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.37e-06	5.27e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTEN—ovarian cancer	1.28e-06	4.93e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AKT1—ovarian cancer	1.23e-06	4.72e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AKT1—ovarian cancer	1.2e-06	4.61e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.17e-06	4.5e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AKT1—ovarian cancer	1.13e-06	4.34e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AKT1—ovarian cancer	1.12e-06	4.3e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AKT1—ovarian cancer	9.57e-07	3.68e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.04e-07	3.48e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AKT1—ovarian cancer	7.39e-07	2.84e-05	CbGpPWpGaD
